Skip to content
naulon
Not checkedNot checked for notices yet.

Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon

Mombo-Ngoma Ghyslain, Kleine Christian, Basra Arti and 10 more

Malaria Journal · 2012

doi:10.1186/1475-2875-11-120 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Background</p> <p>The recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials. However, their recommendation for the treatment of mixed-species malaria and the large-scale use for the treatment of non-falciparum malaria in endemic regions is based on anecdotal rather than systematic clinical evidence.</p> <p>Methods</p> <p>This study prospectively observed the efficacy of artemether-lumefantrine for the treatment of uncomplicated non-falciparum or mixed-species malaria in two routine district hospitals in the Central African country of Gabon.</p> <p>Results</p> <p>Forty patients suffering from uncomplicated <it>Plasmodium malariae, Plasmodium ovale</it> or mixed-species malaria (including <it>Plasmodium falciparum</it>) presenting at the hospital received artemether-lumefantrine treatment and were followed up. All evaluable patients (n = 38) showed an adequate clinical and parasitological response on Day 28 after oral treatment with artemether-lumefantrine (95% confidence interval: 0.91,1). All adverse events were of mild to moderate intensity and completely resolved by the end of study.</p> <p>Conclusions</p> <p>This first systematic assessment of artemether-lumefantrine treatment for <it>P. malariae</it>, <it>P. ovale</it> and mixed-species malaria demonstrated a high cure rate of 100% and a favourable tolerability profile, and thus lends support to the practice of treating non-falciparum or mixed-species malaria, or all cases of malaria without definite species differentiation, with artemether-lumefantrine in Gabon.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov Identifier: NCT00725777</p>

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.